FLT3-ITD and CEBPA mutations predict prognosis in acute myeloid leukemia irrespective of hematopoietic stem cell transplantation

Acute myeloid leukemia (AML) is a heterogeneous disease of varying prognosis. Chromosomal aberrations are found in approximately 55% of adult patients with AML and have high prognostic significance in patient response to therapy, risk of relapse, and overall survival [1 –4]. Three cytogenetic risk groups are currently in use: favorable, intermediate, and adverse. Adverse cytogenetic risk group is largely homogenous and generally includes abnormalities of 3q (i.e. inv(3q), t(3;3), 5q/-5, 7q/-7, abn(17p), t(6;9), 11q23 [except t(9;11)] and complex karyotypes [3].

Source: Biology of Blood and Marrow Transplantation - November 29, 2018 Category: Hematology Authors: Hong Wang, Tian-Tian Chu, Shi-Yu Han, Jia-Qian Qi, Ya-Qiong Tang, Hui-Ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, Chang-Geng Ruan, De-Pei Wu, Yue Han Source Type: research